Please login to the form below

Not currently logged in
Email:
Password:

LMTX

This page shows the latest LMTX news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with AC Immune on tau drug for Alzheimer’s

Lilly partners with AC Immune on tau drug for Alzheimer’s

The company credited with pioneering the tau hypothesis in AD is TauRx, although its aggregation inhibitor LMTX disappointed in an 891-paient phase 3 trial reported in 2016.

Latest news

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    LMTX is thought to reduce the accumulation of the tau protein, which normally stabilizes neurons, into potentially toxic tangles. ... The LMTX data were presented at the Alzheimer's Association International Conference in Toronto.

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics